How India Exports Exemestane to the World

In the United States, Exemestane is approved for medical use, with the brand name Aromasin receiving FDA approval on October 21, 1999. Subsequently, several generic versions have been approved:

- Breckenridge Pharmaceuticals on February 21, 2019
- Cipla Limited on April 27, 2018
- Eugia Pharma Specialities Limited on May 20, 2022
- Qilu Pharmaceutical on April 13, 2020
- Rising Pharmaceuticals on March 10, 2017
- Upsher-Smith Laboratories on July 26, 2017

These approvals indicate a competitive generic market for Exemestane in the U.S. Notably, EUGIA PHARMA SPECIALITIES LIMITED, a significant Indian exporter, received its ANDA approval in May 2022, aligning with its substantial export share. As of March 2026, there are no FDA import alerts or significant regulatory actions against Exemestane products from Indian manufacturers, suggesting compliance with U.S. regulatory standards.

In the European Union, Exemestane is authorized for marketing under various brand names and generic formulations. The European Medicines Agency (EMA) ensures that these products meet stringent safety, efficacy, and quality standards. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of Exemestane products. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions, ensuring that production processes meet high-quality standards.

Exemestane is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its importance in treating hormone-receptor-positive breast cancer globally. The WHO Model List serves as a guide for countries to develop their national essential medicines lists, promoting access to vital medications. Exemestane formulations are standardized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy.

In India, Exemestane is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, Exemestane is not listed under the Drugs (Prices Control) Order (DPCO), and thus, its price is not subject to government-mandated ceilings. For exports, Indian manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national and international regulatory requirements.

The primary patent for Exemestane has expired, leading to the approval and market entry of multiple generic versions. This has intensified competition among manufacturers and exporters, contributing to the substantial export volumes from India. The absence of active patents facilitates broader access and affordability of Exemestane in global markets.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List of Essential Medicines, reaffirming the inclusion of Exemestane in the 24th edition published in September 2025. This highlights the ongoing global recognition of Exemestane's therapeutic value.

In February 2026, the FDA approved a generic version of Exemestane by Breckenridge Pharmaceuticals, further increasing the availability of this medication in the U.S. market. This approval reflects the FDA's commitment to enhancing access to essential medicines through the approval of generics.

These developments underscore the dynamic nature of the pharmaceutical industry and the critical role of regulatory bodies in ensuring the availability and affordability of essential medicines like Exemestane.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of KSMs are imported from China, making the supply chain vulnerable to disruptions. In recent years, environmental regulations in China have led to the shutdown of several chemical manufacturing units, causing supply shortages and price volatility for Indian API manufacturers.

The export market for Exemestane is highly concentrated, with the top five Indian exporters accounting for 78.1% of total exports. INTAS PHARMACEUTICALS LIMITED leads with a 31.1% share, followed by EUGIA PHARMA SPECIALITIES LIMITED (15.4%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (12.3%), MSN LABORATORIES PRIVATE LIMITED (12.0%), and CIPLA LIMITED (7.3%). This concentration poses a risk, as any disruption affecting these key players could significantly impact global supply. To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic API production and reduce dependency on imports. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules used in antibiotics, marking a step towards self-reliance.

Recent geopolitical tensions have severely disrupted global supply chains. In February 2026, the closure of the Strait of Hormuz due to military conflicts halted oil tanker movements, affecting not only energy supplies but also the transportation of pharmaceuticals from India. Approximately 3,200 ships were stalled within the Persian Gulf, causing worldwide logistical shortages and rising prices. Additionally, increased instability in the Red Sea and Suez Canal has forced shipping companies to reroute vessels around Africa’s Cape of Good Hope, adding delays and fuel surcharges. These disruptions have led to increased costs and potential delays in the delivery of Exemestane to key markets.

• Diversify API and KSM Sources: Encourage the development of alternative suppliers for KSMs and APIs to reduce dependency on a single country.

• Strengthen Domestic Manufacturing: Accelerate initiatives like the PLI scheme to enhance local production capabilities for critical pharmaceutical ingredients.

• Enhance Supply Chain Transparency: Implement robust tracking systems to monitor the entire supply chain, enabling quick responses to disruptions.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics strategies to mitigate the impact of geopolitical tensions on transportation.

• Engage in International Collaboration: Work with global regulatory bodies to anticipate and address potential shortages, ensuring a coordinated response to supply chain challenges.

RISK_LEVEL: HIGH